Kidney Week ‘22 Updates
ASN Scientific Briefing & Reception

ProKidney Corp.
Nasdaq: PROK
3 November 2022
Forward-looking Statements

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to financial results, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products, if approved. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A ordinary shares on the Nasdaq; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the impact of COVID-19 or geo-political conflict such as the war in Ukraine on the Company’s business; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
What is ProKidney?

REACT® Aims to be the Disruptive World Leader in Treating Chronic Kidney Disease (CKD)

<table>
<thead>
<tr>
<th>The Problem</th>
<th>The Goal</th>
<th>The Product</th>
<th>The Plan</th>
<th>The Mission</th>
</tr>
</thead>
<tbody>
<tr>
<td>• $130 billion Medicare cost to care for the 40 million CKD/ESKD patients in U.S.</td>
<td>• Stabilize, or reverse the decline of kidney function to delay or prevent dialysis / kidney transplantation</td>
<td>• REACT™ utilizes proprietary autologous cell therapy harvested from the patient’s own kidney</td>
<td>• Phase 3 clinical program received FDA and EMA guidance; trial underway</td>
<td>• Meaningfully reduce the number of people on dialysis or requiring transplantation each year</td>
</tr>
<tr>
<td>• 75 million CKD patients in the U.S. and EU</td>
<td>• Reduce the lifetime cost of care for CKD afflicted patients</td>
<td>• REACT™ includes three specific cell types with the potential to help restore kidney function</td>
<td>• Target commercial launch in 2026</td>
<td>• Target population includes millions of diabetic CKD patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Potential indications expand up to 33 million patients in the U.S. and EU alone</td>
</tr>
</tbody>
</table>
World-class Leadership and Board of Directors

Dr. Tim Bertram, CEO
Dr. Deepak Jain, COO
James Coulston, CFO
Dr. Libbie McKenzie, CMO
Dr. Joe Stavas, SVP Clinical Development
Dr. Darin Weber, SVP Regulatory Development
Ashley Johns, SVP Clinical Operations
Todd Girolamo, Chief Legal Officer & Secretary

Pablo Legorreta, Chairman of the Board

Dr. Tim Bertram
William Doyle
Jennifer Fox
Dr. Alan Lotvin
Dr. John Maraganore
Dr. Brian Pereira
Dr. Uma Sinha
José Ignacio Jiménez Santos
World-class Leadership and Board of Directors

Joining us today

Dr. Tim Bertram, CEO
Dr. Deepak Jain, COO
James Coulston, CFO
Dr. Libbie McKenzie, CMO
Dr. Joe Stavas, SVP Clinical Development
Dr. Darin Weber, SVP Regulatory Development
Ashley Johns, SVP Clinical Operations
Todd Girolamo, Chief Legal Officer & Secretary

Pablo Legorreta, Chairman of the Board
Dr. Tim Bertram
William Doyle
Jennifer Fox
Dr. Alan Lotvin
Dr. John Maraganore
Dr. Brian Pereira
Dr. Uma Sinha
José Ignacio Jiménez Santos
Preclinical Data Suggest REACT Treatment May Improve Kidney Function Via Multiple Mechanisms

**Controls Inflammation**
- VEGF promotes angiogenesis to form new capillaries
- REACT insinuates with mesangial cells

**Integrates**
- REACT replaces podocytes

**Reverses Fibrosis**
- Fibroblasts inactive and basement membrane remodeling takes place
- Cell-cycle restarts and replaces tubular epithelial cells

Preclinical studies in rodents and canines, data on file.
The expanded, target cell therapy product is frozen for storage and injection.

Cells are expanded and then selected renal cells including ureteric bud, cap mesenchyme, and glomerular cells are isolated for preparation.

Renal cortex cells are harvested using a routine kidney biopsy.

Cell therapy product is injected into the patient’s kidneys.
Our Updates at Kidney Week 2022

• Further strong evidence for REACT’s unique mechanism of action
  • Renal Epithelial Cells: an Elite Cell Platform for Kidney Regeneration
  • Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease
  • Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells’ Bioactivity

• Building a deeper CKD patient understanding
  • Prevalence of Chronic Kidney Disease (CKD): Comparison of Real-World Data (RWD) Sources to the USA National Health and Nutrition Examination Survey (NHANES)
  • Gender Differences in CKD Progression: Real-world Data (RWD) Analysis
  • SGLT2i Prescribers Among CKD Patients: Trends in Real-world Data (RWD)
Epithelial cells are the kidney’s “workhorse”
Demonstrate regenerative/modifying properties
The “great communicator” cell in the kidney
Pre-clinical improvement in renal function and mineralization
Human embryologic lineage to progenitor cells
Early signals of renal function improvement in humans
Potential anchor platform for renal regeneration

From “Renal Epithelial Cells: an Elite Cell Platform for Kidney Regeneration?,” Stavas et al, 2022
REACT®: An Elite Cell Platform for Kidney Regeneration?

Renal function in Phase 2 (RMCL-002) study

- Combined eGFR slope improved: -4.63 to -1.69 ml/min/1.73m²/year, p=0.015
- sCr eGFR slope improved: -3.98 to -1.27 ml/min/1.73m²/year, p=0.032
- Median follow up 24.3 months (IQR 18.8-27.7)
- 7 of 22 patients had a positive eGFR slope of +5.88 ml/min/1.73m²
- Log iPTH 0/8 to 0/19, p=0.04
- VEGF ELISA 4.32-7.39 ng/ml in CM

Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells' Bioactivity


SRC/REACT™ in human cell culture, arrows point to expression of relevant markers

FROM "Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease," Narayan et al, 2022
SRC Improves Kidney Microarchitecture

From “Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease,” Narayan et al, 2022
Glomerulogenesis in Rodent Model

From "Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease," Narayan et al, 2022
Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells’ Bioactivity

SRC / REACT:

- May be unique in expressing 8 important renal proteins
- Has gene products and signaling networks which appear compartmentalized within the tubules & glomeruli and participate in processes associated with kidney development
- In culture form organoids with self-assemble into tubules
- Is a standalone platform with nephrogenic potential which may underlie its renal restorative and reparative activity

REACT® May Rescue Highest-Risk Progressors before ESKD

Unrelenting Progression of CKD with No Available Cures

ALBUMINURIA CATEGORIES (mg/g)

<table>
<thead>
<tr>
<th>eGFR CATEGORIES (ml/min/1.73m²)</th>
<th>Mild A1: &lt;30</th>
<th>Moderate A2: 30 - 300</th>
<th>Severe A3: &gt;300</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 90 CKD 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 - 90 CKD 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45 - 59 CKD 3a</td>
<td></td>
<td></td>
<td>REACT</td>
</tr>
<tr>
<td>30 - 44 CKD 3b</td>
<td></td>
<td>REACT</td>
<td>REACT</td>
</tr>
<tr>
<td>&lt; 30 CKD 4</td>
<td>REACT</td>
<td>REACT</td>
<td>REACT</td>
</tr>
</tbody>
</table>

Standard of Care
- Antihypertension
  - ACEi
  - ARB
- Glucose and Inflammation Reduction
  - SGLT2i
  - DPP4
  - GLP-1
  - MRA

REACT® TARGETS
At this stage patients have minimal other treatment options and usually progress to ESKD, dialysis or transplantation.
We are ProKidney

Novel Investigational Cell Therapy Platform in Late-stage Clinical Trials Aimed at Transforming CKD Treatment

- REACT autologous cell therapy currently conducting Phase 3 trials for diabetic CKD
- Pre-clinical through Phase 2 programs in additional indication
- 2019: Acquired technology in development since 2004
- 80+ employees
- $597M received from July 2022 business combination with Social Capital Suvretta Holdings III and concurrent PIPE
- Nasdaq-listed: PROK
- Top shareholder: Pablo Legorreta (~40% of shares outstanding); 4-year lockup on 50% of shares

Existing therapies slow the progression of CKD; REACT’s objective is to reverse it

Summary of Active Clinical Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Objective</th>
<th>Status</th>
<th>Projected Data Readout</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMCL-002 (Ph2)</td>
<td>Safety &amp; efficacy in Stage 3b/4 CKD</td>
<td>Fully enrolled</td>
<td>4Q 2023</td>
</tr>
<tr>
<td>REGEN-003 (Ph2)</td>
<td>Safety &amp; efficacy in Stage 4/5 CKD</td>
<td>Fully enrolled</td>
<td>1H 2023</td>
</tr>
<tr>
<td>REGEN-007 (Ph2)</td>
<td>Bilateral injections Frozen product</td>
<td>Enrolling</td>
<td>2Q/3Q 2023</td>
</tr>
<tr>
<td>REGEN-006 / 016 (Ph3)</td>
<td>US Registration (006) OUS Registration (016)</td>
<td>Enrolling in U.S.</td>
<td>4Q 2024 (006)</td>
</tr>
</tbody>
</table>
Q&A
Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease

- SRC / REACT forms organoids that assemble into tubules in culture in rat model
- The nephrogenic potential of SRC / REACT may underlie its renal reparative and restorative effects

From “Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease,” Narayan et al, 2022